Buy GOSS by Oct 29, 2026.

**GOSS is the ticker for Gossamer Bio, Inc.** (Nasdaq: GOSS), a clinical-stage biopharmaceutical company based in San Diego, California. # What the company does It focuses on developing and commercializing **seralutinib** (also referred to as GB002), an inhaled small-molecule inhibitor targeting PDGFR, CSF1R, and c-KIT pathways. The primary indications are: * Pulmonary arterial hypertension (PAH) * Pulmonary hypertension associated with interstitial lung disease (PH-ILD) Seralutinib is in late-stage development (Phase 3 PROSERA trial completed). The company previously had a collaboration …